nateglinide


Also found in: Medical, Wikipedia.

na·teg·li·nide

 (nə-tĕg′lĭ-nīd′)
n.
An oral hypoglycemic drug, C19H27NO3, that stimulates the release of insulin from the pancreas and is used to treat type 2 diabetes.

[nate-, origin unknown + -glinide, antidiabetic drug suff.; see repaglinide.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
References in periodicals archive ?
Nateglinide is Effective for Diabetes Mellitus with Reactive Hypoglycemia in a Child with a Compound Heterozygous ABCC8 Mutation.
The drugs were categorized into 5 distinct groups: metformin, glyburide, thiazolidinediones (pioglitazone, rosiglitazone), insulin and other oral hypoglycemic agents (chlorpropamide, gliclazide, tolbutamide, glimepiride, sitagliptin, saxagliptin, nateglinide, repaglinide).
Nateglinide, a derivative of meglitinide, is an oral antidiabetic drug used for the treatment of type II diabetes mellitus.
Zhang et al., "Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in Chinese antihyperglycemic agent-naive subjects with type 2 diabetes," Diabetes Technology & Therapeutics, vol.
These include sulfonylureas, such as glipizide and glimepiride, and glinides, such as repaglinide (Prandin) and nateglinide (Starlix).
Nateglinide (Starlix) and repaglinide (Prandin) are the agents in this subclass.
sabdariffa incorporated herbal remedies with CYP3A4 substrates like calcium channel blockers, losartan, and nateglinide [206] could trigger untoward effects.
Bhuniya, "Application of DSC, IST, and FTIR study in the compatibility testing of nateglinide with different pharmaceutical excipients," Journal of Thermal Analysis and Calorimetry, vol.
Nateglinide (Starlix[R]) Thiazolidinediones Rosiglitazone Reduces production of (Avadia[R]) glucose by liver.
Meglitinides (e.g., nateglinide [Starlix[R]], repaglinide [Prandin[R]]) increase insulin secretion by a similar mechanism as sulfonylureas, with similar efficacy in reducing HbA1c (Bennett et al., 2011).